Product image of Microgynon (Ethinylestradiol, Levonorgestrel) supplied by GNH India

Microgynon

Active Ingredient:
Ethinylestradiol, Levonorgestrel
Origin:
EU

Microgynon (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol, the active ingredient in Microgynon, is a combined oral contraceptive presented as a 30 µg ethinylestradiol / 150 µg levonorgestrel tablet for oral use. It prevents pregnancy by inhibiting ovulation and altering cervical mucus and the endometrium in women of reproductive age. The product is indicated for reliable, reversible birth control in women who wish to avoid pregnancy.

GNH India supplies Microgynon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Bayer Plc

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Microgynon, a combined oral contraceptive, acts on the hypothalamic‑pituitary‑ovarian axis to prevent pregnancy.

  • Contraception (prevention of pregnancy): provides reliable, reversible birth control for women of childbearing potential.
  • Regulation of menstrual cycles: helps establish predictable monthly bleeding patterns.
  • Treatment of moderate acne: reduces inflammatory lesions by modulating androgen activity.

How It Works

  • Microgynon combines ethinylestradiol, a synthetic estrogen, with levonorgestrel, a progestogen. The estrogen component suppresses follicle‑stimulating hormone (FSH) release, while the progestogen inhibits luteinising hormone (LH) surge, preventing ovulation. Additionally, levonorgestrel thickens cervical mucus and alters the endometrial lining, creating an environment hostile to sperm penetration and implantation.

Side Effects

Adverse reactions may occur with any hormonal contraceptive.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Headache: tension‑type or migraine‑like pain.
  • Breast tenderness: discomfort or swelling of the breasts.
  • Spotting between periods: irregular light bleeding.

Serious or Rare Side Effects

  • Deep vein thrombosis: blood clot formation in deep veins.
  • Pulmonary embolism: clot migration to the lungs.
  • Severe hypertension: markedly elevated blood pressure.

Precautions & Warnings

Use Microgynon only after medical assessment of risk factors.

  • Smoking: avoid if over 35 years and a smoker due to increased thrombotic risk.
  • History of thromboembolism: contraindicated because of clotting potential.
  • Migraine with aura: avoid because of elevated stroke risk.
  • Liver disease: use with caution; hepatic impairment may alter hormone metabolism.
  • Drug interactions: review concomitant medications for possible efficacy reduction.
  • Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and heat.

Avoid Interactions

Microgynon may interact with several medicines that affect hormone metabolism.

Major Interactions (Avoid)

  • Antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): may reduce contraceptive efficacy.
  • Rifampin: decreases circulating hormone levels, increasing pregnancy risk.
  • St. John's wort: herbal inducer that can lower oral contraceptive effectiveness.

Moderate Interactions (Monitor Closely)

  • Antifungal azoles (e.g., ketoconazole): may increase hormone concentrations, raising side‑effect potential.
  • Macrolide antibiotics (e.g., erythromycin): can elevate plasma levels of ethinylestradiol.
  • Selective serotonin reuptake inhibitors (e.g., fluoxetine): may affect hormone metabolism and require monitoring.

Frequently Asked Questions

Microgynon is a combined oral contraceptive containing ethinylestradiol and levonorgestrel. It is prescribed to prevent pregnancy in women of reproductive age by inhibiting ovulation and creating conditions that are unfavorable for fertilisation and implantation.

Ethinylestradiol suppresses the release of follicle‑stimulating hormone, while levonorgestrel blocks the luteinising hormone surge needed for ovulation. Together they also thicken cervical mucus and alter the endometrium, reducing the likelihood of sperm passage and embryo implantation.

The prescribed regimen for Microgynon is determined by the treating healthcare professional. Typically, the tablet contains 30 µg ethinylestradiol and 150 µg levonorgestrel and is taken once daily as directed by the prescriber.

Microgynon is intended to prevent pregnancy and should not be used once pregnancy is confirmed. Its safety in breastfeeding has not been fully established; women should discuss any concerns with their healthcare provider before starting or continuing therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Microgynon contains a low‑dose estrogen (30 µg ethinylestradiol) combined with levonorgestrel, a second‑generation progestogen. Compared with higher‑dose formulations, it may offer a lower risk of estrogen‑related side effects while maintaining effective contraception. Choice of pill depends on individual risk factors and physician assessment.

Microgynon tablets should be stored at ambient temperature below 25 °C, in their original packaging, protected from moisture and direct heat. Do not store in bathrooms or near windows where temperature fluctuations occur.

Microgynon is taken orally, usually once each day at the same time, with or without food. The typical pack contains 21 active tablets followed by a placebo week, during which withdrawal bleeding occurs.

Serious risks include thromboembolic events such as deep vein thrombosis, pulmonary embolism, stroke, and severe hypertension. Women with a history of clotting disorders, smoking over age 35, or certain cardiovascular conditions should avoid use and discuss alternatives with their doctor.

Microgynon is contraindicated in women with known or suspected pregnancy, active thromboembolic disease, uncontrolled hypertension, severe liver disease, or a history of estrogen‑dependent tumors. It should also be avoided in smokers over 35 years of age and in those with migraine with aura.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Levonorgestrel

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT